Text Size

Group CBT for Depression and AOD Disorders (BRIGHT2)

This study has been completed.
Sponsor:
Collaborator:
Behavioral Health Services, Inc.
Information provided by (Responsible Party):
RAND
ClinicalTrials.gov Identifier:
NCT01154309
First received: June 29, 2010
Last updated: November 10, 2011
Last verified: November 2011
History of Changes
  Purpose

The investigators will adapt and test an existing treatment (group CBT for depression) for use in outpatient substance use treatment settings as delivered by trained substance use counselors. The investigators expect that treatment will lead to improved depression and substance use outcomes.


Condition Intervention Phase
Depression
Substance Use
 Behavioral: Group CBT for Depression and AOD Disorders
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Group Cognitive Behavioral Therapy for Depression and Alcohol and Other Drug Disorders

Resource links provided by NLM:

MedlinePlus related topics: Depression
U.S. FDA Resources

Further study details as provided by RAND:

Primary Outcome Measures:
  • Reductions in depressive symptoms as measured by the BDI II [ Time Frame: Post treatment ] [ Designated as safety issue: No ]
  • Reductions in AOD use [ Time Frame: Post treatment ] [ Designated as safety issue: No ]

Enrollment: 73
Study Start Date: September 2006
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Clients are invited to attend 18 group CBT sessions
 Behavioral: Group CBT for Depression and AOD Disorders
18 sessions of 2-hour group CBT
No Intervention: 2
Clients receive usual care

Detailed Description:

Aim 1. To adapt an existing group therapy (CBT for depression), creating a manualized treatment and accompanying implementation measures and tools for use with clients with persistent depressive symptoms and AOD disorders and to obtain preliminary assessments of the treatment from patient and provider perspectives.

Aim 2. To conduct a pilot test of the revised treatment in which we (a) demonstrate that when the therapy is implemented with fidelity, clinically significant reductions in depressive symptoms and AOD use occur; (b) estimate the likely effect size; and (c) investigate the underlying mechanisms of change, including both cognitive-behavioral and group processes and their relationship to depression and AOD treatment outcomes.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Enrolled in outpatient substance abuse program
  • BDI II score >13
  • Probable alcohol or substance use problem

Exclusion Criteria:

  • Cognitive impairment (Short Blessed > 10)
  • Probably bipolar or schizophrenic disorder
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01154309

Locations
United States, California
Behavioral Health Services, Inc
Gardena, California, United States, 90249
Sponsors and Collaborators
RAND
Behavioral Health Services, Inc.
Investigators
Principal Investigator: Katherine E Watkins, MD, MSHS RAND
  More Information

No publications provided

Responsible Party: RAND
ClinicalTrials.gov Identifier: NCT01154309     History of Changes
Other Study ID Numbers: R01DA020159
Study First Received: June 29, 2010
Last Updated: November 10, 2011
Health Authority: United States: Federal Government

Keywords provided by RAND:
Depression
Substance Use
Group Cognitive Behavioral Therapy

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 23, 2013